Supporting Innovative ALS Treatments with Clene Nanomedicine & Synapticure
January 23, 2025
Anovo is proud to announce a new partnership with Clene Nanomedicine, Inc. and Synapticure Inc., supporting their efforts to bring hope to people living with Amyotrophic Lateral Sclerosis (ALS). As part of this collaboration, Anovo is now dispensing CNM-Au8®, Clene’s innovative gold nanocrystal suspension, for their Early Access Program (EAP) patients.
What is Amyotrophic Lateral Sclerosis (ALS)?
ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. Over time, the disease leads to a loss of muscle control and function, often impacting the ability to move, speak, swallow, and even breathe. The disease has a profound impact on patients and their families, making the search for innovative therapies like CNM-Au8® critical.
Clene Nanomedicine and Synapticure Partner with Anovo
Our collaboration with Clene Nanomedicine and Synapticure underscores our dedication to improving access to promising therapies. By dispensing this treatment through Clene’s Early Access Program, Anovo is helping to ensure patients and families receive the care and support they need to navigate the challenges of ALS.
Related Posts
Why Exclusivity Matters: Redefining Patient-Centricity in Rare and Ultra-Rare Drug Commercialization
In the rare disease space, every patient story is deeply personal, and every barrier to access feels monumental. From navigating…
June 4, 2025
The Heart of Our Success: How Our HR Team Fuels Growth & Culture
At Anovo, we know that our success starts with our people. Behind every dedicated team member, every seamless patient experience,…
May 19, 2025
Investing in Training to Elevate Patient Care
At Anovo, we believe that exceptional patient support starts with a well-trained, knowledgeable team. As we continue to grow, we’ve…
April 1, 2025
